Diabetes Discourse

The COORDINATE Study evaluated patients with cardiovascular disease and type 2 diabetes who encounter barriers in receiving newer diabetes medications. To better understand these gaps in care, Dr. John Buse speaks with one of the researchers, Dr. Jennifer Green from Duke University in Durham, North Carolina.

Counseling patients with obesity who are on GLP-1 receptor agonists can be challenging. How can we leverage the biology of GLP-1 receptor antagonists to improve weight loss while avoiding side effects? Dr. John Buse speaks with a leading expert in the field, Dr. Ania Jastreboff, about the role of GLP-1 receptor agonists in weight loss.

There are immeasurable benefits to exercise, but the hard part for patients may be getting started. How can we help our patients make exercise a part of their lives? Dr. John Buse speaks with Dr. Abbie Smith-Ryan, a Professor of Exercise Physiology at the University of North Carolina – Chapel Hill, about the key benefits of exercise and how to encourage them for various patient populations.

New guidelines published by Obesity Canada take a deep dive into pharmacotherapy and feature the latest recommendations on comorbidities and decision tools. To better understand the impact of these guidelines, Dr. John Buse speaks with one of the guidelines authors, Dr. Sue Pedersen, a specialist in endocrinology and metabolism.

New guidelines published by Obesity Canada take a deep dive into pharmacotherapy and feature the latest recommendations on comorbidities and decision tools. To better understand the impact of these guidelines, Dr. John Buse speaks with one of the guidelines authors, Dr. Sue Pedersen, a specialist in endocrinology and metabolism.

New research on once-daily semaglutide for adolescent patients with obesity may alter clinicians’ approach to care. What do we need to know? Dr. John Buse speaks with one of the study’s investigators, Dr. Silva Arslanian, from the University of Pittsburgh to dive into this clinical data and explore how these results may change the treatment landscape.

What does the latest research on glycemia reduction show us about the impact of glucose-lowering medication in combination with metformin on microvascular and cardiovascular outcomes in patients with type 2 diabetes? Dr. John Buse speaks with one of the study’s investigators, Dr. Jennifer Green, a Professor of Medicine at Duke University, about this emerging data.

The GRADE study demonstrated the efficacy of different treatment options for patients with type 2 diabetes. To learn more about these treatment options, Dr. John Buse joins one of the study’s investigators, Dr. Deborah Wexler from Harvard Medical School and the Massachusetts General Hospital Diabetes Center, to dive into this study.

Research continues to emerge on the bionic pancreas and its capabilities, and a recent study shows how it can count carbohydrates and lower A1c for patients with type 1 diabetes. To find out how it does, Dr. John Buse is joined by Dr. Steven Russell, an Associate Professor of Medicine at Harvard Medical School at the Massachusetts General Hospital.

Recent research has explored the efficacy of open source automated insulin delivery devices for patient with type 1 diabetes. What did these results tell us? Dr. John Buse speaks with Dr. Martin de Bock, a pediatric endocrinologist at the University of Otago in Christchurch, New Zealand, to dive deeper into this research.